Santhera Pharmaceuticals Holding AG Stock
Stocks
SANN
CH1276028821
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Swiss Exchange
03:30:07 29/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 14.96 CHF | -0.66% |
|
+1.77% | +18.73% |
| 23/10 | Santhera's Partner Seeks Marketing Permit in South Korea for Duchenne Muscular Dystrophy Treatment | MT |
| 23/10 | Nxera Pharma Files South Korean Marketing Application for DMD Drug | MT |
| Market Cap | 229M 276M 248M 207M 387M 26.28B 392M 2.74B 1.09B 13.75B 1.04B 1.01B 43.66B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 249M 300M 270M 226M 422M 28.61B 427M 2.98B 1.19B 14.97B 1.13B 1.1B 47.53B | EV / Sales 2026 * |
2.63x | EV / Sales 2027 * | 2.1x |
| Free-Float |
84.85% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| SANN | Delayed | |
CBOE
| 0QN1 | Real-time | |
|
OTC Markets
| SPHDF | Delayed | |
|
Deutsche Boerse AG
| S3F0 | Delayed | |
|
Börse Stuttgart
| S3F0 | Delayed | |
|
Tradegate
| S3F0 | Real-time | |
|
Boerse Muenchen
| S3F0 | Real-time |
Last Transcript: Santhera Pharmaceuticals Holding AG
| 1 week | +1.77% | ||
| Current month | -3.48% | ||
| 1 month | -1.71% | ||
| 3 months | -1.97% | ||
| 6 months | -18.52% | ||
| Current year | +18.73% |
| 1 week | 13.84 |  | 15.46 |
| 1 month | 13.42 | | 15.98 |
| Current year | 11.7 | | 18.84 |
| 1 year | 10.06 | | 18.84 |
| 3 years | 7.21 | | 18.84 |
| 5 years | 5 | | 20.3 |
| 10 years | 5 | | 820 |
| Manager | Title | Age | Since |
|---|---|---|---|
Orlando Oliveira
CEO | Chief Executive Officer | 50 | 15/07/2026 |
Catherine Isted
DFI | Director of Finance/CFO | 51 | 24/02/2025 |
Marc Schrader
COO | Chief Operating Officer | 55 | 01/09/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Meier
CHM | Chairman | 64 | 30/06/2022 |
| Director/Board Member | 58 | 04/04/2017 | |
Bradley Meyer
BRD | Director/Board Member | 47 | 27/06/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 22/1/24 | Buy | 30,228 | 0.2396% | |||
| 6/7/23 | Buy | 2,000 | 0.0016% | |||
| 11/1/22 | Buy | 30,000 | 0.0549% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.66% | +1.77% | +41.13% | +29.86% | 278M | |
| +0.50% | +0.36% | +55.89% | +129.96% | 1,143B | |
| +0.86% | +4.50% | +42.43% | +86.15% | 647B | |
| -0.14% | -1.07% | +25.42% | +105.85% | 506B | |
| -0.05% | +2.28% | +49.14% | +67.74% | 384B | |
| -0.63% | -4.97% | +60.15% | +37.06% | 350B | |
| +0.34% | +2.15% | +25.26% | +54.27% | 293B | |
| -0.45% | +1.16% | +1.74% | +26.08% | 265B | |
| +0.87% | +2.94% | +55.18% | +72.74% | 242B | |
| +0.08% | +1.72% | +32.15% | +107.78% | 197B | |
| Average | +0.42% | +1.01% | +38.85% | +71.75% | 402.78B | |
| Weighted average by Cap. | +0.77% | +0.71% | +42.63% | +89.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 94.7M 114M 102M 85.77M 160M 10.87B 162M 1.13B 451M 5.69B 428M 419M 18.06B | 116M 139M 125M 105M 196M 13.27B 198M 1.38B 550M 6.94B 523M 512M 22.04B |
| Net income | - | - |
| Net Debt | 20.3M 24.47M 21.96M 18.39M 34.35M 2.33B 34.76M 243M 96.67M 1.22B 91.84M 89.9M 3.87B | 13.4M 16.15M 14.49M 12.14M 22.67M 1.54B 22.95M 160M 63.81M 805M 60.62M 59.34M 2.56B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | CHF 14.96 | -0.66% | 117,054 |
| 27/10/26 | CHF 15.06 | +5.76% | 166,430 |
| 26/10/26 | CHF 14.24 | +2.89% | 67,826 |
| 23/10/26 | CHF 13.84 | -1.98% | 41,973 |
| 22/10/26 | CHF 14.12 | -4.72% | 19,740 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SANN Stock
Select your edition
All financial news and data tailored to specific country editions
